CSF2 and neoplasm: The combination of neoantigen and GMCSF could achieve better performance, which could decrease 36.3% of the tumour volume (MHCI + GMCSF) and 45.5% of the tumour volume (MHCII + GMCSF) on Day 22 (Fig. 3b).